Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02904954 · ClinicalTrials.gov registry record · Phase 2
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT02904954 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 60 participants.
The verdict
NCT02904954, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to find out the effectiveness of the drug durvalumab (MEDI4736) with or without stereotactic body radiation therapy (SBRT) as treatment for stage I (tumors \> 2cm), II, and IIIA non-small cell lung cancer (NSCLC) prior to surgery and one year following surgery.
Interventions
- DRUG Durvalumab
- OTHER Durvalumab plus SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-12-02 |
| Est. Completion | 2022-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02904954
The ClinicalTrials.gov registry entry for NCT02904954 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT02904954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02904954 about?
NCT02904954 is a clinical study titled "Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer". The purpose of this study is to find out the effectiveness of the drug durvalumab (MEDI4736) with or without stereotactic body radiation therapy (SBRT) as treatment for stage I (tumors \> 2cm), II, and IIIA non-small cell lung cancer (NSCLC) prior to surgery and one year following surgery.
What is the current status of trial NCT02904954?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2016-12-02. Estimated completion is 2022-10-04.
What interventions are being tested in trial NCT02904954?
The interventions under investigation include: Durvalumab (DRUG), Durvalumab plus SBRT (OTHER).
Who is sponsoring clinical trial NCT02904954?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.